Yes, IL-13 is a target for therapeutic intervention. Monoclonal antibodies against IL-13 or its receptor are being developed and used to treat conditions like asthma and atopic dermatitis. These therapies aim to reduce IL-13-mediated inflammation and tissue remodeling, improving clinical outcomes.
